Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FURTHER study of furmonertinib in EGFR- or HER2-mutant non-small cell lung cancer
NL-OMON59037Phase 1Active, not recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by ArriVent BioPharma. Primary endpoint: Primary endpoint(s). Started Apr 2023; status: active, not recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59037.